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Abstract 
 
Role of Nucleosome Remodeling Factor (NURF) in Tumorigenesis Using a 
Breast Cancer Mouse Model 
 
A thesis submitted in partial fulfillment of the requirements for the degree of 
Master of Science in Human and Molecular Genetics at Virginia Commonwealth 
University  
By  
Aiman Saud Alhazmi 
Virginia Commonwealth University, 2012 
 
Director: Joseph W. Landry, Ph.D. 
Assistant Professor  
Department of Human and Molecular Genetics 
 
Understanding the impact of epigenetic mechanisms on tumorigenesis is 
essential, as epigenetic alterations are associated with tumor initiation and 
progression.  Because epigenetic changes are reversible, they are potential 
targets for cancer therapy.  Nucleosome Remodeling Factor (NURF) is a 
chromatin-remodeling complex that regulates gene expression by changing 
nucleosome positioning along the DNA sequence.  Previous studies have shown 
a role for NURF in embryonic development as well as regulating genes involved 
in tumor progression.  In this work we investigated the impact of eliminating 
NURF function in tumorigenesis in vivo.  BALB/c mice challenged with syngeneic 
67NR breast cancer cell lines, injected into the mammary fat pad, lacking NURF, 
due to knockdown of its essential subunits Bptf, showed reduction in tumor 
 XIII 
growth comparing to control tumors.  The observed reduction in tumor growth 
was abrogated in immunodeficient mice lacking a functional immune system.   
Bptf KD and control 67NR cells grew at similar rates in vitro.  Similar findings 
were observed in our lab using 66cl4 breast cancer cell lines.  Using 
immunofluorescence staining, no significant difference in CD8+, CD4+, NK and 
MDSC cells infiltrations into the tumor microenvironment was observed in 66cl4 
tumors. Preliminary results from 67NR tumors suggested more CD4+ and CD8+ 
cells.  Gene expression profile of tumor tissues from BALB/c mice injected with 
67NR and 66cl4 cell lines showed enrichment of genes associated with immune 
response.  Our findings suggested a role of the immune system in targeting 
tumor cells lacking Bptf in vivo.   
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1- Introduction 
 
1.1- Epigenetics: 
 During embryonic development cells undergo transitions from the 
pluripotent stage to more specialized and lineage committed stages. This 
process is achieved by changing gene expression at different stages to ensure 
the availability of essential proteins for each cell type (Berdasco & Esteller, 
2010).  The control of gene expression in the cells is a highly regulated process 
that ensures normal growth, differentiation, function and life span of the cell.  One 
important level of controlling gene expression within the cells is epigenetic 
regulation of the genome.  
  Epigenetics is defined as heritable regulation in a gene expression pattern 
that is not due to alteration in the DNA sequence.  These regulations modify DNA 
or chromatin structure ( Moazed, 2011).  Epigenetic regulation of the genome is 
important in maintaining the normal gene expression, and account for different 
biological mechanisms in eukaryotic cells, including X chromosome inactivation 
and genomic imprinting.  In addition, many pathological conditions are due to 
abnormal alterations in the epigenome including Angelman’s syndrome, Prader-
Willi Syndrome and different types of cancers (Berdasco & Esteller, 2010) 
(Egger, et al., 2004).   
As alterations of the epigenetic mechanisms have been found in many 
malignant cells, it has been proposed that epigenetic abnormalities are involved 
in disease etiology and progression.  Unlike alterations in DNA sequence, 
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epigenetic modifications are reversible.  Because they are reversed, they are 
excellent therapeutic targets. We must understand the role of these mechanisms 
in the pathological conditions to design therapeutic approaches that reverse the 
abnormal changes (Sharma, et al., 2010). 
 
1.1.1 - Epigenetic Mechanisms: 
 There are four epigenetic mechanisms involved in regulating gene 
expression, and interactions between these mechanisms ensure stable 
expression of the genome.  These mechanisms are DNA methylation, histone 
modification, chromatin remodeling complexes and microRNA (Kim, et al., 2009).  
 
1.1.2- Chromatin Structure: 
 In eukaryotic cells, genomic material is compacted and localized within the 
nucleus in the form of chromatin.  Chromatin is composed of an interaction 
between DNA and proteins in which 147 base pairs of DNA is wrapped around 
histones H2A, H2B, H3 and H4 (Luger, et al., 1997).  This level of compacting 
affects exposure of the DNA sequence and can hinder direct interaction with 
DNA binding factors such as transcription factors.   
 
1.1.1.2-Chromatin Remodeling Complexes: 
The need for chromatin remodeling complexes arises from the fact that 
the highly compacted chromatin within the nucleus requires mechanisms to 
rearrange nucleosome positions.  This makes DNA element accessible for 
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different proteins that promote DNA replication, gene expression, and DNA repair 
mechanisms (Wang, et al., 2007). ATP-dependent chromatin-remodeling families 
include switching defective/sucrose (SWI/SNF) nonfermenting, imitation switch 
(ISWI), chromodomain helicase DNA binding (CHD) and inositol requiring 80 
(INO80) function to rearrange nucleosomes positions.  These families share an 
ATPase domain, and individual complex in each family has different subunits that 
account for its functions (Clapier & Cairns, 2009).    
 
1.1.1.2.1-Nucleosome Remodeling Factor NURF: 
NURF complex was discovered in D.melanogaster (Tsukiyama & Wu, 
1995), and subsequently its homolog has been isolated and found conserved in 
H.sapiens indicating the importance of this complex (Barak, et al., 2003).  NURF 
is a member of ISWI family of chromatin remodeling complexes that share a 
conserved ATPase domain (Clapier & Cairns, 2009).   
 
1.1.1.2.1.1- Structure: 
 Mammalian NURF is composed of three subunits; BPTF (Bromodomain 
and PHD-finger Transcription Factor), SNF2L (Sucrose Non-Fermenting 2 Like) 
and RBAP46/48 (Barak, et al., 2003) (Figure 1).  Studies in Drosophila NURF 
(dNURF) found that the Bptf homolog NURF301 and the Snf2l homolog IWSI are 
essential for the complex function (Xiao, et al., 2001). BPTF is the largest and 
exclusive subunit to mammalian NURF (Barak, et al., 2003). It is a large protein 
(~311Kda) that has important domains including; acidic batch, DDT and PHD 
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finger domains in the N-terminus, and poly-glutamate repeats, PHD-domain and 
bromodomain in the C-terminus.  The second essential subunit is SNF2L which 
have character features of the ISWI family of chromatin remodeling include the 
ATPase domain, HAND, SANT and SLIDE domains (Alkhatib & Landry, 2011).     
 
 
Figure 1) 
     a) 
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b)              
       
Figure 1: Nucleosome Remodeling Factor NURF's Subunits. 
 a) The three subunits of the NURF complex. Black is BPTF (Bromodomain and PHD-
finger Transcription Factor subunit), Red SNF2L (Sucrose Non-Fermenting 2 Like 
subunit) and Blue is pRBAP46/48 (Retinoblastoma-associated Protein 46 and 48). b) 
Diagram shows the conserved domains in BPTF subunit between H.sapiens and 
M.musculus. Red, Green, Black, Blue and pink represent bromodomain, PHD finger, 
polyglutamate repeats, DDT and acidic patch domain respectively.  The figure adapted 
from (Alkhatib & Landry, 2011).  
 
  
1.1.1.2.1.2- Function: 
 
The role of NURF as a chromatin remodeler is dependent on a 
nucleosome (Tsukiyama & Wu, 1995).  Localization of NURF to its target 
sequences can be through; 1- Interaction with transcription factors as is the case 
for GAGA factor and progesterone receptor PR that subject NURF to HSP70 and 
MMTV promoters respectively (Badenhorst, et al., 2002) (Di Croce, et al., 1999). 
2 - Recognition of histone modifications. e.g. binding of the PHD finger in the Bptf 
C-terminal with histone 3-lysine 4 trimethyl (H3K4me3) (Wysocka, et al., 2006). 3 
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- Presence of a specific DNA binding domain. However, a specific DNA binding 
domain for NURF has not been identified yet, its presence is not unexpected 
since DNA binding sequence has been identified for Bptf related protein Fetal 
Alz-50-reactive clone 1 (FAC1) (Jordan Sciutto, et al., 1999). 4- Recognition of 
histone variants.  The NURF essential subunit BPTF is localized in nucleosome 
with H2A.Z variant (Goldman, et al., 2010).  Once recruited, NURF utilizes ATP 
to slide the nucleosome position in both directions and expose the DNA 
sequence to different regulatory proteins (Hamiche, et al., 1999) (Badenhorst, et 
al., 2002).  
 
Many studies have shown that NURF is involved in a number of important 
developmental and signaling pathways including TGFβ/Smad, JAK/STAT and 
Heat Shock (Badenhorst, et al., 2002) (Landry, et al., 2008) (Kwon, et al., 2008).  
In agreement with these findings, eliminating NURF function in a mouse model 
by knockout of its largest subunit Bptf is lethal which demonstrates the 
requirement of NURF in embryonic development through regulating important 
pathways such as Nodal/Smad signaling pathway (Landry, et al., 2008). 
Moreover, the same work showed that Bptf knockout in mouse embryonic stem 
cells (ESCs) prevents their ability to develop and form teratomas after injection 
into NOD/SCID (Non-obese diabetic /Severe combined immunodeficiency).   
Collectively, these findings demonstrate the requirement of NURF in cell 
development and differentiation in vivo.  In addition, gene expression profile from 
embryonic stem cells (ESCs), mouse embryonic fibroblasts (MEFs) and double 
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positive DP thymocytes identify a number of genes that are involved in different 
aspects of carcinogenesis as Bptf dependent genes (Landry, et al., 2008) 
(Landry, et al., 2011) these include adherence genes (E-Cadherin, N-Cadherin, 
Vimentin and Fibronectin) (Makrilia, et al., 2009) and a group of major 
histocompatibility class I (MHC-I) and  class II (MHC-II) genes (Campoli & 
Ferrone, 2008).  Moreover, in the level of chromatin structure, KD of Bptf leads to 
alterations in nucleosome occupancy localized with DNA binding site for CTCF 
an important chromatin regulator at important sites such as promoters and 
insulators (Millau & Gaudreau, 2011).   
Together, these findings suggested that NURF, as an epigenetic 
mechanism, might have a role in tumorigenesis.   
  
 
1.2- Cancer: 
Cancer is a term for multiple diseases that share common characteristics 
responsible for the associated malignant phenotype.  According to the world 
health organization, cancer is the main cause of mortality in the world (Ferlay , et 
al., 2010).  Although cancer is a focus of extensive amount of research 
worldwide, and much improvement has occurred in terms of detection and 
treatment of tumor lesions, the number of new cases and death rates are still 
high.  In the United States, where cancer is the second cause of death, the 
estimated number of new cancer cases in 2012 is around 1.6 million cases, and 
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1,500 cancer patients die every day according to 2012 American Cancer 
Society’s report (American Cancer Society. , 2012).  
Malignant tumors generate from set of cells that undergo uncontrolled 
cellular division.  As malignant cells develop, they progressively accumulate 
more alterations in the genomic and epigenomic levels that lead to profound 
changes in their gene expression profile and growth advantage (Sharma, et al., 
2010).  Although malignant tumors can be developed from different tissues and 
organs, all tumor types share common capabilities that ensure a tumor’s survival 
(Hanahan & Weinnerg, 2011).  One of these capabilities is the ability of tumor 
cells to escape the effect of the host immune system.  
 
 
1.2.1- Role of the Immune System in Cancer: 
1.2.1.1- The Immune System: 
 The mammalian immune system is divided into the innate immune system 
and the adaptive immune system; both systems are occupied by cellular and 
molecular components, and are activated against microbial pathogen, infection 
and tumor cells.  The innate immune system’s cellular component includes 
macrophages, dendritic cells (DCs), polymorphonuclear granyolocyte (PMNs) 
and natural killer cells (NKs), while the adaptive immune system is mainly 
composed of T-lymphocyte and B-lymphocytes (Medzhitov, 2007).  Both systems 
differ in terms of onset of response and the level of specificity against pathogens. 
While the innate immune system responds faster and is less specific against 
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foreign or non-self antigens, the adaptive immune system has a slower but more 
pronounced and specific response.  Cells from both systems are involved in 
mediating response against tumor cells.  Natural killer cells, as a part of the 
innate immune response, and cytotoxic T-cells, as a part of the adaptive immune 
response, are the two main cell types that have cytotoxic activity against tumor 
cells (Russell & Ley, 2002).  
 
1.2.1.1.1- Natural Killer Cells: 
Natural killer cells, as the name depicts, mediate cytotoxic activity upon 
activation against target cells (Kiessling, et al., 1975).  They have a lymphocytic 
origin similar to T- and B-lymphocyte, but they are considered an innate immune 
response, as they don’t undergo clonal selection for specific antigens like in T-
lymphocyte and B-lymphocyte receptors (Biron , et al., 1987).  The cytotoxic 
activity of the NK cells can be mediated through secretion of cytotoxic granules 
containing perforin and granzyme (Russell & Ley, 2002) or through death 
receptors of TNF (Tumor Necrosis Factors) family ligands including TRAIL (TNF 
related apoptosis induced ligand) and FasL that are expressed in the surface of 
the NK cells (Zamai, et al., 1998).  NK cells express two types of cell membrane 
receptors; inhibitory receptors include KIR (killer cell immunoglobin-like receptor) 
in human, CD94/NKG2A in human and mice, and Ly49 in mice; and activating 
receptors e.g. NKG2D and NCR (Natural Killer Receptor).  These receptors have 
an important role in distinguishing target cells from host cells, and proper 
signaling through both receptors ensures the normal function of NK cells 
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(Langers, et al., 2012).  Ligands for the inhibitory receptors include a set of MHC-
I molecules that are normally express on surface of nucleated cells and therefore 
they inhibit the NK cells from targeting these cells.  Down regulation of these 
molecules can trigger the NK cells response against these cells as missing self-
signal.  Ligands for the activating receptors include Rae-1 and H-60 in mice and 
MICA/B in human, which are non-classical MHC-I molecules found to be 
overexpressed in malignant cells (Groh, et al., 1999) (Diefenbach, et al., 2001).  
Studies have shown that NK cells infiltration into tumor tissues associated with 
favorable prognosis in cancer patients (Ishigami, et al., 2000) (Coca, et al., 
1997). 
 
1.2.1.1.2- Cytotoxic T Cells: 
Cytotoxic T-cells (CTLs) or CD8+ T-lymphocytes are important cellular 
components of the adaptive immune system that are responsible to mediate 
cytotoxic activity against infected and tumor cells.  Upon activation, CTLs 
mediate killing of target cells through two mechanisms, similar to NK cell, perforin 
mediated cytotoxicity and Fas/FasL pathway (Russell & Ley, 2002). CTLs 
recognize MHC-I molecules, which are expressed on all nucleated cells. 
Malignant cells express tumor-associated antigens (TAAs) that can be presented 
in the cell surface by the MHC-I through the antigens presenting machinery APM.  
TAAs include peptides of mutated genes or germ line genes that are abnormally 
expressed in transformed somatic cells (Restifo, et al., 2012). Infiltration of CTLs 
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into tumor tissues is associated with favorable outcomes in cancer patients 
(Naito, et al., 1998).    
 Antigens loading on the MHC-I are a sequential mechanism that starts by 
degradation of ubiqutinated proteins in the cytoplasm through immunoproteosom, 
which contains Psmb9 and Psmb8 catalytic subunits (Angeles, et al., 2012).  The 
resulted peptides are transported to the endoplasmic reticulum (ER) through 
heterodimer of two transporter proteins TAP1 and TAP2 (ATP-binding cassette-1 
and 2).  Inside the ER the peptides loaded into MHC-I molecule, which is 
composed of α chain and β2m, in the ER membrane through tapasin (Tapbp) 
(Seliger, et al., 2000).  The resultant complex, MHC-I and the peptide, is then 
transport to the cell membrane.  
 
1.2.1.1.3- T-helper Cells: 
The second cellular component of the adaptive immune system is T-
helper cells. This set of cells characterized by expressing CD4 co-receptor on the 
cell surface and recognizing antigens such as TAAs that are presented on MHC-
II molecules, which express in the antigen presenting cells APCs (macrophage, 
dendritic cells and B-cells) (Pieters, 1997).  The T-helper cells further subdivided 
into Th-1 and Th-2 based on the cytokines expression (Kidd, 2003).  In context of 
antitumor response, Th-1 is known to augment the CTLs activity and enhance 
the antitumor response through promote APCs activation and secretion cytokines 
such as INF-γ (Yu & Fu, 2006), which induce expression of MHC-I molecules in 
tumor cells. (Ikeda, et al., 2002).  Th-2 has a pro-inflammatory role and studies 
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have shown that these cells might promote tumor growth in some type of cancers 
(Kidd, 2003).  
 
1.2.1.2- Cancer Immunosurveillance:  
 Cancer immunosurveillance is defined as the ability of the host immune 
system to detect and eliminate tumor cells (Burnet, 1970).  While the main 
function of the immune system is protecting the host from foreign cells, the 
tumor-associated antigens expressed by a tumor cells are the signals that 
distinguish malignant cells from host cells and trigger the immune system 
attention to these cells (Smyth, et al., 2001).  The concept of cancer 
immunosurveillance is supported by number of findings in mouse models lacking 
essential components of the immune response, as well as observations from 
cancer patients (Dunn, et al., 2004).  For instance, mice with non-functional 
adaptive immune response due to homozygous knockout of the recombinase 
activating gene RAG-2, which is important in maturation of functional T-
lymphocyte and B-lymphocyte receptors ( Shinkai, et al., 1992), were more 
susceptible to develop tumors following treatment with a carcinogen compound 
(Methylcholnthrene MCA) compared to wild type mice (Shankaran, et al., 2001).  
Also, the innate immune system has been found to play a role in tumor 
immunosurveillance.  Mice treated with monoclonal antibodies that inhibit NK 
cells developed more MCA-induced tumors comparing to control mice (Smyth, et 
al., 2001).  The role of the immune system has been observed in human.  
Epidemiological studies have shown a relative increase in cancer incidence rate 
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among immunocompromised patients (Birkeland, et al., 1995). Also, histological 
studies have shown localization of the immune cells into tumor tissues, which 
indicates an activation and recruitment of these cells into the tumor environment 
(Naito, et al., 1998).  Isolating CD8+ T-cells as well as antibodies against specific 
tumor associated antigens from cancer patients support the role of adaptive 
immune system against growing tumors in human (Dunn, et al., 2004).  
 
1.2.1.3- Evasion of the Immune System:   
The existence of cancer as a pathological condition in immunocompetent 
individuals led to suggest a continuous interaction between tumor cells and 
immune system which has two end points; either the immune system 
successfully eliminates the tumor cells (immunosurveillance) or the malignant 
cells evade the immune system (evasion of the immune response) (Dunn, et al., 
2004).   
Findings from tumor injection studies in mice lacking important immune 
system components suggest an additional role of the immune system against 
tumor cells described as immunoediting (Dunn, et al., 2004).  Work by 
Shankaran et al. showed that tumors that grew in RAG2 -/- mice without 
functional adaptive immune system failed to form tumors upon re-injection into 
wild type mice, but were able to form tumors when they were re-introduced into 
mice with suppressed immune system (Shankaran, et al., 2001).  On the other 
hand, tumors that grew in mice with a functional immune system were able to 
form tumors when they re-injected into wild type mice.  From these observations, 
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it has been suggested that the level of immunogenicity of tumor cells is affected 
by the action of immune response against tumor cells, and the immune system 
acts as a selective factor that eliminates the highly immunogenic cells (easily 
detected by immune system) and allows survival of cells that have low 
immunogenic phenotype. 
 
 During tumor progression, malignant cells accumulate genetic and 
epigenetic alterations that lead to generate a heterogeneous population in the 
tumor microenvironment.  The antitumor effect of the immune system acts as a 
selective agent against the malignant cells (Vesely, et al., 2011).  Cells with 
immunogenic phenotype are eliminated while cells that develop resistance 
mechanisms can avoid destruction.  Eventually, this set of cells progressively 
develops and becomes predominant in the tumor site (Birkeland, et al., 1995).  
Mechanisms that can be developed by tumor cells to avoid the immune system 
include; reducing tumor immunogenicity, reducing the effect of the CTL and NK 
cytotoxicity through overexpressing anti-apoptotic molecules or depressing the 
death signaling pathways; secretion of cytokines that can either inhibit the 
immune cells activity e.g. interleukin 10 (IL-10), tumor growth factor beta (TGF-β) 
and vascular endothelial growth factor (VEGF) (Khong & Restifo, 2002) or recruit 
and amplify immunosuppressor cells such as myeloid derived suppressor cells 
(MDSCs) and regulatory T-cells (Vesely, et al., 2011).  
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1.2.1.3.1-Reduce Tumor Cell Immunogenicity: 
 Down regulation of antigens presenting MHC-I molecules is one way 
which tumor cells can avoid cytotoxic T cells (Garrido, et al., 1997), and has been 
reported in many tumor types (Algarra, et al., 1997).  Down regulation of MHC-I 
molecules can be through irreversible genetic alterations that affect MHC-I genes 
or through reversible epigenetic silencing.  In addition, reduction in tumor cells 
immunogenicity can be mediated by silencing the antigens presenting machinery 
(APM) genes including Psmb8, Psmb9, TAP-1, TAP2 and tapasin (Seliger, 
2008).  However, as MHC-I molecules are expressed in all nucleated cells, they 
serve as inhibitory ligands for the inhibitory receptors on NK cells.  
 
1.2.1.3.2-Recruitment and Amplification of MDSCs: 
 Myeloid derived suppressor cells (MDSCs) are a group of heterogeneous 
immature myeloid cells.  An increase in number of MDSCs has been associated 
with tumors in mouse models and cancer patients (Gabrilovich & Nagaraj, 2009).  
In response to different cytokines that are released within tumor 
microenvironment, which include (granulocyte macrophage colony stimulating 
factor (GM-CSF), interleukin-1 beta (IL-1 β), tumor growth factor beta (TGF-β) 
and prostaglandins, there is an expansion and activation of the MDSCs 
population (Naiditch, et al., 2011).  In the tumor microenvironment, MDSCs have 
a negative effect on the immune response through secretion of 
immunosuppressive factors e.g. arginase and inducible nitric oxide (iNOS) that 
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cause depletion of important amino acids for T-cell activation such as arginine 
and cysteine (Gabrilovich & Nagaraj, 2009).  
 
1.2.1.3.3-Regulatory T-cells: 
 Regulatory T-cells are a group of cells that regulate the host immune 
response through suppression of CD4 and CD8 cells, and they infiltrate into 
tumor microenvironment (Piersma, et al., 2008).  Depletion of these cells 
promotes autoimmune response against self-antigens (Yu & Fu, 2006).  CD4 
regulatory T-cells (CD4+ CD25+ Fox3+ (fork-head box protein3)) are well studied 
regulatory T-cells, and they mediate their suppresser activity through cell-cell 
interactions, secretion of inhibitory cytokines such as IL-10 and TGF-β or 
depleting IL-2 (Schametterer, et al., 2012).  Also, studies have shown that CD8 
regulatory T-cells infiltrate into tumor tissues and might have similar 
immunosuppressive function (Wang, 2008). 
 
 
1.3- Hypothesis: 
Along with mutations, epigenetic alterations are associated with tumor 
development and progression.  Previous findings indicated that there is a role of 
NURF in embryonic development, teratomas formation and regulating important 
genes in cancer suggest a role of NURF in tumorigenesis.  We hypothesized that 
eliminating NURF function might reduce tumor growth in vivo.  Toward this end 
we proposed the following aims;  
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Aim 1- To investigate tumor growth in mice after injection of Bptf KD 
67NR breast cancer cells.  Using a syngeneic mouse model, 67NR Bptf 
knockdown and control breast cancer cells were injected into mammary fat pad 
of BALB/c mice and NOD SCID gamma (NSG) mice.  After 3 weeks, the tumors 
were surgically removed and tumor weights were measured.  Tumors were also 
processed in aims 2 and 3.  
Aim 2- To measure immune cells infiltration into the tumor site 
following Bptf KD.   As findings from the previous experiments suggested a role 
of the immune system in the observed phenotype, we screened for immune cells 
infiltration into tumor sites. Using immunofluorescence staining, frozen 
histological sections were stained with CD8a, CD4, NKp46 and CD11b antibody 
for CTL, T-helper, NK and MDSC cells, respectively. These experiments 
attempted to determine if reduction in tumor growth are the result of increased 
immune cell infiltration   
Aim 3- To identify gene expression profile in Bptf KD from tumor 
tissues.  The findings from aim 1 suggested that Bptf KD promote the antitumor 
immune response against the tumor cells.    Tumors from BALB/c mice injected 
with Bptf KD and control 67NR and 66cl4 cell lines were subjected for microarray 
analysis. 
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2- Methods and Materials: 
 
2.1- Mice and Cell Lines: 
BALB/c and NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ female mice (NOD scid 
gamma NSG mice) were provided from the Jackson Laboratory (Bar Harbor, 
ME).   Mouse breast cancer cell lines (4T1, 66cl4 and 67NR) were obtained from 
Dr. Fred R. Miller at Wayne State University (Detroit, MI). Mice were harvested at 
the barrier facility in the Molecular Medicine Research Building, Virginia 
Commonwealth University (Richmond, VA).  Cells were maintained in 1X high 
glucose DMEM Dulbecco’s Modified Eagle Medium provided by Invitrogen life 
technology (Grand Island, NY).  The media contains 1X Non-essential amino 
acids, 2 mM L-Glutamine both provided by GIBCO Invitrogen (Grand Island, NY), 
10 % fetal bovine serum, 1X penicillin and streptomycin provided by Mediatech 
Inc. (Manassas, VA).  Cells transfected with Bptf short hairpin was maintained in 
media contains 5 µg/ml of Puromycin, as a selective agent, provided by 
Invitrogen (Grand Island, NY).  Cells were maintained in 6 wells, 12 wells plates 
or 10 cm dishes at 37 °C and 5 % CO2 in tissue culture incubator.   
 
2.2- Bptf Stable Knockdown Cell Lines: 
 In order to generate stable Bptf knockdown (KD) cell lines, the Retro-X™ 
system (cat. No. 631598) and pSIREN-Retro-Q vector (Cat. No. 631526) were 
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used, provided by Clontech (Mountain, CA) to generate retrovirus vector with 
short hairpin specific sequence targeting Bptf gene.  
 Two short hairpins were used (KD-1 and KD-2) to knockdown Bptf; KD-1 (5’-
CGACGATGACTCCGATTATT-TCAAGAG-AATAATCGGAGTCATCGTCG-3’); 
KD-2(5’-GGCGAAAACCAAGAGTACAT-TCAAGAG-
ATGTACTCTTGGTTTCGCC-3’).  Non-specific sequence was used as a control 
(5’-GTGCGTTGCTAGTACCAACTT-TCAAGAG-3’).  pSIREN-Retro-Q vector 
contains shRNA sequence was transfected into PT67 packaging cell line to 
generate retrovirus vector. PT67 cells were plated in medium without Puromycin 
for 2-3 days to generate the virus.  Then, the medium, which contains the virus, 
was collected, filtered and added to 67NR breast cancer cells in 6 wells plate for 
2-3 days.  The medium was then replaced with medium containing Puromycin (5 
μg/ ml) for selection of cells that integrated the viral genome.  Each well 
represents a single transduction event.  
 
2.3- Cell Counting: 
Cells were plated in 10 cm dish with 10 ml of media for 48 hours.  The 
media was removed and cells were washed with 1 ml of 0.25 % Trypsin and 1 
mM EDTA and again incubated in 1 ml of Trypsin + EDTA for 1 to 2 minutes in 
the incubator to release the cells from the dish.  Next, 3 to 5 ml of media was 
added, and cells were counted using the hemocytometer slide or the Cell meter 
Auto T4 from Nexcelom Bioscience (Lawrence, MA). 0.2 % Trypan blue provided 
from Sigma-Aldrich (St. Louis, MO) was used to count cells for injection. 
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2.4- Population Doubling Time: 
 In 3 plates of 12 wells plate cells were seeded at 1X104 cells/ ml with 2 ml 
of media. For each plate 4 wells were used for control and 4 wells for knockdown 
cells. Cells were counted at 24 hours, 48 hours and 72 hours as one plate for 
each time point. The population doubling time was measured using doubling time 
calculator software from Roth V. 2006 http://www.doubling-
time.com/compute.php.  
 
 
2.5- Mice Injection and tumors collection: 
 6 to 8 weeks of age female mice were anesthetized with isoflurane 
provided by Clipper distribution company (St. Joseph, MO), and were injected 
with 1X105 67NR control shRNA and Bptf shRNA knockdown cells into the 
mammary fat pad.  Cells were diluted into  2X106  cells/ml, and 50 μl was injected 
into the mice.  Three weeks post injection; mice were sacrificed using carbon 
dioxide.  Tumors were surgically removed, and immediately frozen with liquid 
nitrogen in 15 ml conical tube.  Tumor weight was measured by weighing each 
15 ml conical tube before and after a tumor is added.  The difference between 
the two weights was used as the tumor weight.  Tumor samples were stored at -
80°C.   
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2.6- Western Blotting: 
Proteins were extracted from tumor tissues and monolayer cells using TRI 
Reagent® (as a lysis reagent) provided by Sigma-Aldrich (St. Louis, MO). Tumor 
tissues were chopped and 0.05 - 0.1 g of tissue was homogenized with 1 ml of 
TRI reagent using electronic homogenizer.  Monolayer cells were washed with 1x 
PBS, then 1 ml of TRI was added and incubated for 5 minutes.  Then, the 
homogenates were transferred into 1.5 ml tubes, and 200 μl of chloroform was 
added and the samples were incubated for 10-15 minutes.  Then, samples were 
centrifuged for 15 minutes at 20,000 rcf (relative centrifugal force) at 4°C.  Three 
layers were formed; an aqueous phase contains the RNA, an interphase contains 
the DNA and an organic phase contains the proteins were in (bottom layer).  
After removing the aqueous and interphase, 1 ml of isopropanol was added and 
the tubes were incubated at room temperature for 10 minutes.  Then, the 
samples were centrifuged at 20,000 rcf for 15 minutes at 4°C.  The supernatants 
were discarded and 1 ml of 0.3 M guanidine in 95% ethanol was added for 
overnight wash at 4°C on shaker.  Then, the guanidine was removed by 
centrifugation and 1 ml 100 % ethanol was added and incubated for overnight at 
4°C on shaker.  After removing the ethanol, 250 μl of 8 M urea in 1% SDS was 
added, and samples were incubated at 65°C overnight.  Protein concentration 
was measured using Bio-Rad Dc Protein Assay provided by Bio-Rad Laboratories 
(Hercules, CA) using BSA standards.  The proteins were dissolved in 2 mg/ml 
concentration. 50 µg of protein was loaded into 4% gel for SDS-PAGE, and run 
for 1 hour at 200 V and 300 mA.  Next, proteins were transferred into 
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polyvinylidene fluoride PVDF membrane provided by Bio-Rad Laboratories 
(Hercules, CA) for 17 hours at 20 V and 30 mA.  After the transfer the membrans 
were blocked with 5% non-fat dry milk for 1 hour.  Then, Bptf primary antibody 
was used at 1:5000 dilution and incubated for overnight at 4°C.  Following three 
times washing with PBST (phosphate buffer saline with 0.1% Tween 20) for 5 
minutes each, the membrans were incubated with ECL peroxidase labeled anti-
rabbit secondary antibody at 1:10,000 dilution for 1 hour.  The plots were then 
washed for 5-10 minutes with PBST for 3 times and developed using supersignal 
West Femto Substrate from Thermo Scientific (Rockford, IL). 
 
2.7- Immunohistochemistry: 
Frozen tumor tissues were embedded in O.C.T compound (Optimal 
Cutting Temperature) from Sakura Finetek (Torrance, CA).  Tissue samples were 
sectioned at -20 to -25°C with 5 μm thickness using vibratome ultra pro 5000. 
Cryosections were fixed with acetone for 10 minutes, followed by 10 minutes air 
dry. Sections were then washed two times with 1 X PBS for 5 minutes each. 
Then, sections were blocked for 1 hour using 1% BSA (bovine serum albumin) 
was provided by Sigma-Aldrich (St. Louis, MO).  Then, primary antibodies were 
added at 1:50 dilution for 1 hour. Four rat anti-mouse primary antibodies were 
used for CD8, CD4, CD11 and NK cells as follow (CD8a cat. No. 550281), (CD4 
cat. no.550280), (NKp46 cat no. 560754) and (CD11b cat. no. 557395) provided 
by BD Biosciences (San Jose, CA).  Sections were then washed three times with 
PBST for 5 minutes and secondary antibody was added. Secondary antibody 
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was goat anti-rat IgG-FITC antibody Lot# K1711 provided by Santa Cruz 
Biotechnology (Santa cruz, CA). Then, Slides were washed three times with PBS 
for 5 minutes each and vectashield® was used as mounting media provided by 
Vector Laboratories, Inc (Burlingame, CA).  Sections were examined using 
Olympus BX41 Fluorescence microscope under FITC channel. 
 
2.8-RNA Extraction and Quantitative RT-PCR:  
 Total RNA was extracted using TRI reagent® (as a lysis reagent) provided 
by Sigma-Aldrich (St. Louis, MO) from the breast cancer cell lines grown in 10 
cm plate. The cells were washed with 1X PBS and 1 ml of TRI reagent was 
added and incubated for 5 minutes.  Then, the contents were transferred to 1.5 
ml centrifuge tubes and 200 μl chloroform was added.  Samples were mixed by 
vortexing and incubated for 10-15 minutes.  Tubes were then centrifuged at 
21,000 rcf for 15 min at 4°C.   The resulted aqueous phase, which contains the 
RNA, was transferred into a new 1.5 ml tubes.  100 μl of acidic phenol was 
added and samples were centrifuged.  RNA precipitation was achieved by adding 
250 μl of isopropanol and 250 μl of RNA precipitation solution as ¼ the volume of 
the TRI reagent for each compound.  RNA precipitation solution composed of 
(1.2 M NaCl and 0.3 M disodium citrate).  After mixing the contents and 
incubating the tubes for 10 minutes at room temperature, the tubes were 
centrifuged at 21,000 rcf for 15 minutes at 4°C.  The resulted pellets were 
washed for two times with 70% ethanol and RNA was dissolved in 50 μl 
molecular grade water.  RNA integrity was investigated by running 1.5% agarose 
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gel to check for the presence of two un-smeared rRNA bands.  The absorbance 
at 260 and 280 wavelengths was measured by NanoDrop® ND-1000 
spectrophotometer provided by Thermo scientific (Wilmington, DE). 
 RNA was converted to cDNA using Superscript™III kit from Invitrogen life 
technology (Grand Island, NY).  1 μg of total RNA was used in reaction mixture 
that include 10 μl of 2X RT reaction mix, 2 μl reverse transcriptase and volume of 
molecular grad water to make the total volume 20 μl.  The thermo cycle was as 
follow: 25°C for 10 minutes; 50°C for 30 minutes and 85°C for 5 minutes.  Then, 
1 μl of RNase H was added and tubes incubated for 20 minutes at 37°C. 
 Quantitative RT-PCR was used to confirm the microarray results. SYBR 
green ABsolute SYBR Green ROX Mix from Thermo Scientific (Rockford, IL) was 
used.  The reaction mixture was prepared as follow: 5 μl of primers 280 nM 
(forward and reverse primers), 5 μl of cDNA and 10 μl of SYBR Green ROX Mix.  
The qRT-PCR condition was as follow: 95ºC for 15min, then 50 cycles of 95ºC 
for 10 seconds, 60ºC for 30 seconds and 72ºC for 30 seconds. Disassociation 
curve cycle has been added at the end.   Gene expression was calculated using 
comparative Ct value.  β-actin was used as endogenous gene to normalize the 
gene expression in control and knock-down samples.  
-Primer Sequences 
Primers were designed using www.ncbi.nlm.nih.gov/tools/primer-blast/ , and 
provided by eurofins mwg|operon (Huntsville, AL) (Table 1). 
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Table 1) 
Gene 
Symbol   
Primer Sequence 
H2-Mb2 
F 5'-TGTGCCACCCACACCCAACCTT-3' 
R 5'-GTCTCCATTGGGCTGAGCCGT-3' 
Cxcl16 
F 5'-GACCCTGCCAGGCGATGGCAAC-3' 
R 5'-GGCTTCCCCCACACACGCTTT-3' 
Cxcl9 
F 5'-TCAGCTCTGCCATGAAGTCCGC-3' 
R 5'-ACTAGGGTTCCTCGAACTCCACAC-3' 
H2-Dma    
F 5'-TCCCAGTGTCCAGAGGTTTGCCTGT-3' 
R 5'-TGCCTAGCACACCGAGGCCA-3' 
β-actin 
F 5'-CCCCATTGAACATGGCATTG-3' 
R 5'-ACGACCAGAGGCATACAGG-3' 
Lmp7 
F 5'-TTGGCCAAGGAGTGCAGGTTGTAT-3' 
R 5'-GTCCCGAGAGCCGAGTCCCAT-3' 
Tap2 
F 5'-CGCCTTTGCAAGCGCCATCTTT-3' 
R 5'TCGAGTTCAGCTCCCCTGTCTT-3' 
Tapbp 
F 5'CTGGCTGGTAGCTGCCTACTGGACC-3' 
R 5'-TGAGGGTGGCTTCCACAGACGA-3' 
Lmp2 
F 5'-CTCTGCTGAGATGCTGCGGGC-3' 
R 5'-CCACTGCTGTTCCCGCTGACAC-3' 
H2-D1 
F 5'-GAGCCTCCTCCGTCCACTGACTC-3' 
R 5'-CCAGGCAGCTGTCTTCACGCTTTA-3' 
Ccnd1a 
F 5'-CACAACGCACTTTCTTTCCA-3' 
R 5'-ACCAGCCTCTTCCTCCACTT-3 
Ccnd1b 
F 5'-GATTTGGCACCTCTCAGCTC-3' 
R 5'-TGGTGAACAAGCTCAAGTGG-3' 
 
 
  
2.9- Microarray Analyses: 
Microarray experiments and analysis were performed in Dr. Catherine I. Dumur’s 
Laboratory at Molecular Diagnostic Laboratory.  RNA extraction, microarray 
analysis and statistical analysis were performed as described in (Singh, et al., 
2011) (Dumur, et al., 2008).  Tumor tissues subjected to gross histological 
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analysis using hematoxylin and eosin stain to determine percentages of tumor 
cells, necrotic and stromal cells before tissues were isolated for the RNA 
extraction.  Most of the tumors have 100 % to 70 % tumor tissues and necrotic 
tissues, if present, were selected out by macrodissection.  TRIZOL reagent and 
MagMAX™-96 for microarray total RNA isolation kit provided from Life 
technology Ambion® (Austin, TX) were used to extract total RNA from frozen 
tumor tissues in the automated magnatic particle processor MagMAX express 
from Applied Biosystem. Then, using 2100 Bioanalyzer from Agilent 
Technologies (Foster City, CA) 1 μl of sampes was applied to RNA ND8000 Lab 
Chips® to assess the RNA purity and integrity at 260, 270 and 280 nm. Then, 5 
μg of total RNA were used for cDNA synthesis and in vitro transcription to 
generate biotinylated cRNA using the GeneChip® 3’ IVT express kit provided by 
Affymetrix (Santa Clara, CA).  Hybridization conditions for the fragmented cRNA 
on the GeneChip®Mouse Genome 430A 2.0 Array were 16 hours at 60 rpm 
(round per minutes) at 45°C, and 10 μl of fragmented cRNA were used.  Then, 
using Affymetrix fluidics work station the microarrays were washed and stained 
with streptavidin phycoerythrin provided from Molecular probes (Eugene, OR).  
The microarrays were then scanned as previously described using the Affymetrix 
GeneChip® scanner 3000 and data were saved as .dat and .cel files. The array 
quality was accepted if the 3’/5’ ratio of the housekeeping gene (GAPDH) is less 
than three and the present gene % is more than 40%.   
Microarray Statistical analysis was performed as previously described 
(Singh, et al., 2011). Log-scale robust multiarray analysis RMA was used for 
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noise correction, normalization and estimation for probe expression.  Relative 
difference between control and KD samples were analyzed using two-sample-t-
test for each pairwise comparison, and to determine differentially expressed 
probes at univariat level α-level equal 0.01 was used.  q-value was used to 
correct for multiple comparisons in the microarrays experiments, each p-value 
was corrected for multiple testing using FDR false discovery rate < 15%. 
Gene Ontology analysis was performed using DAVID the Database for 
Annotation, Visualization and Integrated Discovery v 6.7  
http://david.abcc.ncifcrf.gov/.  Functional annotation chart tool was used to 
determine the highest enrichment terms in the probe set lists that have 2 or more 
fold changes.   
 
3.10- Statistical Analysis: 
Significance difference between control and knockdown samples was 
determined using two-tail student t-test.
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3- Results 
 
3.1- Knockdown of NURF Function Reduces Tumor Growth in a Mouse 
Model.  
NURF is a chromatin-remodeling complex that regulates gene expression 
by changing nucleosome position.  Work by Landry et al., showed that NURF is 
essential during embryonic development, as mouse lacking Bptf, which is an 
essential subunit of NURF (Xiao, et al., 2001) is not viable (Landry, et al., 2008).  
They also showed that ESCs lacking Bptf were unable to form teratomas in 
NOD/SCID mice.  Gene expression profile of Bptf KO ESCs, MEFs and DP 
thymocyte revealed a role of Bptf in regulating number of genes involved in 
cancer progression including MHC-I genes, N-cadherin and E-cadherin genes 
(Landry, et al., 2008) (Landry, et al., 2011).  Together these findings led us to 
hypothesized that eliminating NURF function might reduce tumor growth in vivo.  
To test our hypothesis we chose a BALB/c mouse breast cancer model 
developed by Fred Miller.  This model has many advantages including (i) it is 
very well characterized mouse model (Aslakson & Miller, 1992), (ii) allows to 
investigate tumor cells growth in vivo with intact immune system (Ottewell, et al., 
2006), (iii) it resembles human breast cancer metastasis (Lelekakis,, et al., 1999) 
and (iv) it is convenient to use as cells can be easily injected into mammary fat 
pad and form tumors within 3 to 4 weeks.  In this model there are five cell lines 
(4T1, 66cl4, 4T07, 168 FARN and 67NR) that were originally derived from a 
single spontaneous mammary tumor developed in a BALB/c mouse.  These cell 
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lines differ in their ability to metastasize; 4T1 cells disseminate through blood and 
metastasize to the lung, liver, brain and bone; 66cl4 cells disseminate through 
lymph and metastasize to the lung; 168FARN and 4T07 disseminate through 
lymph and blood, respectively but fail to metastasize and 67NR cells have the 
ability to form primary tumors, but unable to disseminate from the primary site 
(Aslakson & Miller, 1992).  This work focused on 67NR cell lines.  The impact of 
NURF in the two metastatic cell lines (4T1 and 66cl4) is a subject of another 
work done by Suehyb Alkhatib in our lab.  
First, we wanted to confirm the expression of NURF in the selected cell lines.  
Work done by S. Alkhatib showed the presence of NURF subunits (Bptf, Snf2L 
and pRbAp46/48) in these cell lines (Figure 2).  
Figure 2) 
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Figure 2: Expression of NURF Subunits in Breast Cancer Cell Lines.   
Expression of Bptf, Snf2L and pRbAp46/48 NURF's subunits in 66cl4, 4T1, 4T07, 
168FARN and 67NR breast cancer cell lines using Western Blotting. Ponceau stain was 
used to confirm equal protein loading. 
 
Next, eliminating functional NURF can be achieved by knockdown of its 
essential and exclusive subunit Bptf (Xiao, et al., 2001) (Landry, et al., 2008). 
Toward this end we generated stable Bptf KD 67NR cell lines using retrovirus 
vector to introduce short hairpin targeting Bptf.  We used two shRNAs (named as 
knockdown-1 (KD-1) and knockdown-2 (KD-2)) to create two different Bptf KD 
cell lines to control for off target effect.  A nonspecific RNA sequence was used 
as a control (Figure 3).  
 
Figure 3) 
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Figure 3: Bptf KD in 67NR Breast Cancer Cell Lines.   
Western Blotting is showing Bptf KD using two different shRNAs (KD-1 and KD-2). Non-
specific RNA sequence was used as a control.  Ponceau stain was used to confirm 
equal protein loading. 
Next, In order to investigate roles of NURF in tumor growth we injected 
1X105 67NR cells into the mammary fat pad of syngeneic BALB/c mice.  Mice 
injected with three group of cells; (i) cells transfected with non-specific shRNA as 
a control, (ii) cells transfected with KD-1 and (iii) cells transfected with KD-2.  The 
tumors were collected three weeks after injection.  We observed significant (p-
value < 0.005) reduction in tumors weight and tumors formation in both KDs 
comparing to the control tumors (Figure 4).  While all the mice injected with the 
control cells formed tumors except one, only 3 out of 13 and 6 out of 16 of mice 
injected with the KD-1 and KD-2 cell lines, respectively, formed tumors.  
Knockdown of Bptf in the tumor tissues was maintained comparing to the control 
tumors (Figure 5).  Similar reduction in tumor growth but not in frequency was 
observed with the 66cl4 cell lines (by Suehyb Alkhatib, data not shown).  These 
findings suggested that eliminating NURF has a negative effect on tumor growth. 
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Figure 4) 
 
Figure 4: Knockdown of NURF Function Leads to Reduction in Tumor Growth in 
vivo. 
Tumors weights form mice injected with control, KD-1 and KD-2 67NR breast cancer cell 
lines.  Significant (p-value < 0.005) reduction was observed in KD-1 and KD-2 tumors 
relative to the control tumors.  Error bar represent standard deviation of 13 tumors for 
each group.  
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(Figure 5)  
                
Figure 5: Bptf KD in Tumor Tissues. 
Western Blotting is showing Bptf expression level in tumor tissues injected with control, 
KD-1 and KD-2 67NR breast cancer cell lines. Non-specific control shRNA sequence 
was used as a control.  Ponceau stain was used to confirm equal protein loading.  
 
3.2 – 67NR cells Lacking NURF Proliferate Normally in vitro. 
     The observed reduction in vivo can be due to a role of NURF in cellular 
growth, as a result KD of Bptf can lead to reduce the cell growth efficiency in 
vitro.  To exclude the possibility that the observed reduction in tumor growth was 
due to effect on cellular growth, we measured the population doubling time of the 
67NR control and Bptf KDs cell lines in vitro (Figure 6).  In this experiment, the 
required time for an entire population of cells to double their number was 
measured.  No significant difference was observed between the control cell lines 
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and the two KD cell lines.  Similar result was observed with 66cl4 breast cancer 
cell lines (S. Alkhatib, data not shown).  This observation suggested that the 
observed reduction in tumor growth (Figure 4) is due to an effect in vivo.  
Figure 6) 
 
Figure 6: Normal Proliferation Rate for 67NR Cells Lacking NURF in vitro. 
Population doubling time experiment for control, KD-1 and KD-2 67NR breast cancer cell 
lines.  1✕104 cells/ ml were plated in 12 wells plate, and cell count was measured at 
three time points 24, 48 and 72 hours. The error bars represent standard deviation of 
three independent biological replicates for each cell line.  
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3.3 - Reduction in Tumor Growth from Bptf KD 67NR Cells Is Dependent on 
The Immune System. 
Data from the previous experiments suggested a role of NURF in tumor 
growth in vivo.  One of the challenges that tumor cells must overcome in order to 
progressively grow in vivo is avoiding the antitumor immune response.  The 
effect of the host immune system on tumor growth have been supported by 
number of observations, and the ability of the tumor cells to evade the immune 
system is considered a hallmark of tumor cells (Hanahan & Weinnerg, 2011).  
The observed deregulation of MHC-I and MHC-II genes in Bptf knockout in vitro 
(Landry, et al., 2008) suggest that the immune system might be responsible for 
the observed phenotype.   We anticipated that the observed reduction in tumor 
growth might be due to active immune response against the tumor cells.  Toward 
this end, we investigated the effect of Bptf KD in tumorigenesis in 
immunodeficient mouse model.  We chose NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ 
mouse model.  This model has two mutations in non-obese diabetic background 
that lead to a complete absence of the adaptive and innate immune systems.  
The first mutation is loss of function mutation in Prkdc gene, which is important 
for functional T-cell and B-cell receptors; as a result it leads to eliminate the 
adaptive immune cells.  The second mutation is knockout for Il2 receptor gamma 
gene, which encodes important subunit of the IL2 receptor, which plays a role in 
lymphocytes and other immune cells maturation resulting in elimination of the 
innate immune cells e.g. NK cells (DiSanto, et al., 1995).  Using this model, 
1X105 67NR cancer cells were injected into the mouse mammary fat pad.  Three 
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weeks after injection, all mice developed tumors. The tumors were collected and 
no significant difference in tumor weights was observed in both knockdowns 
comparing to the control tumors (Figure 7).  This finding suggests that the 
observed reduction in tumor growth in the BALB/c mice is due to immune 
system. 
Figure 7) 
 
Figure 7: NURF Does Not Affect Tumor Growth in NSG mice: 
Tumor weights from mice injected with control, KD-1and KD-2 67NR breast cancer cell 
lines. The error bars represent standard deviation for 5 mice per each group. 
 
3.4- Normal Immune Cells Infiltration into the Tumor Tissues. 
Results from the previous experiments suggested a role of the immune 
system in the observed reduction in tumor growth.  The cellular component of the 
immune system plays important roles in mediating the antitumor response 
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against transformed cells.  Studies in mice have shown the role of both the innate 
and adaptive immune cells in mediating cytotoxic activity against malignant cells. 
Mice lacking CTLs, T-helper or NK cells are more prone to develop induced 
tumors compared to wild type mice (Dunn, et al., 2004).  Another group of cells 
that infiltrates into the tumor tissues is MDSCs which have an 
immunosuppressive role against immune cells (Gabrilovich & Nagaraj, 2009).  
We hypothesized that the reduction in tumor growth might be associated with 
increase of CTLs, T-helper or NK cells or decrease of the MDSCs infiltration into 
the tumor tissues.   
In order to screen for the immune cells infiltration into the tumor tissue, we 
used immuofluorescent technique to stain histological sections of tumors tissues. 
We stained the tumor tissues derived from the BALB/c mice injected with 67NR 
(Figure 8) and 66cl4 (Figure 9) cell lines using fluorochrome conjugated 
antibodies for CD8, CD4, NK and CD11.  The preliminary results from the 67NR 
tumors showed slight increase of the CD8, CD4 and decrease in CD11b cells.  
However, these results represent one tumor for KD-1 and two tumors for KD-2.  
More tumors are required to determine the significance of this finding.  (Figure 8 
a-d).  For the 66cl4 tumors no significant difference in CD8, CD4, NK and MDSC 
cells infiltration were observed between the control and knockdown tumors 
(Figure 9 a-d).  Although, there is no significant difference in the immune cells 
infiltration in the 66cl4 tumors, it could be possible that there is increase in the 
activity and the efficiency of the effector immune cells in targeting the knockdown 
tumors. (Rosenberg, 2001) (Zitvogel, et al., 2006).   
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Figure 8) 
 
Figure 8: Immune Cells Infiltration into Bptf KD 67NR Tumors: 
Number of immune cells infiltrated into the 67NR primary tumors (control, KD-1 and KD-
2) developed in the mammary fat pad of BALB/c mice using immunofluorescence 
staining.  Antibodies were used for a) CD8a for CTL cells, b) CD4 for T-helper cells, c) 
NKp46 for NK cells and d) CD11b for MDSCs.  Counts were obtained as average cells 
count from 10 fields relative to the control ((cell counts for KD / Cell count for control) X 
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100).  Only one tumor for KD-1 and 2 tumors for KD-2 are shown. Error bar in the KD-2 
represent standard deviation for 2 tumors. 
Figure 9) 
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Figure 9: Normal Immune Cells Infiltration into Bptf KD 66cl4 Tumors: 
Number of immune cells infiltrated into the 66cl4 primary tumors (control, KD-1 and KD-2) 
developed in the mammary fat pad of BALB/c mice using immunofluorescence staining.  
Antibodies were used for a) CD8a for CTL cells, b) CD4 for T-helper cells, c) NKp46 for NK 
cells and d) CD11b for MDSCs.  Counts were obtained as average cells count from 10 fields 
relative to the control ((cell counts for KD / Cell count for control) X 100). Error bars represent 
standard deviation for 3 biological replicates for each group.  
 
 
3.5- Microarray Data Show Overexpression of Genes Involved in Immune 
Response. 
 The significant reduction in tumors weight from the two different cell lines (67NR 
and 66cl4) in BALB/c mice after reducing NURF function suggested a role for NURF in 
regulating genes that has a role in tumor survival in vivo.  In order to identify NURF 
dependent genes we measured gene expression profile of tumor tissues obtained from 
the BALB/c mice injected with the 67NR and 66cl4 breast cancer cell lines (Figure 10).  
Microarray analyses were performed in collaboration with Dr. Catherin Dumur at Virginia 
Commonwealth University. Tumor tissues were subjected to gross histological 
examination using hematoxylin and eosin (H&E) stain to determine the percentage of 
tumor cells. The tumor content of the tissues used for the arrays was 70% to 100% and 
necrotic tissues, if present, were removed by macrodissection.  The following 
microarray data are preliminary; the 67NR data represent two tumors for the KD-2 and 
three tumors for the control, and the 66cl4 data represent two tumors for the KD-1, KD-2 
and control.  More tumors will be used to complete three biological replicates for the 
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control, KD-1 and KD-2.  Unsupervised hierarchical cluster analyses based on 22,960 
probe sets showed clustering for KD and control samples (Figure 10 a, c data 
obtained from Dr. Dumur).  There were 88 probe sets in the 67NR tumors and 105 
probe sets in 66cl4 tumors that showed significant deregulation between the control and 
KD (p-value < 0.01, False Discovery Rate FDR < 15%) (Figure 10 b, d data obtained 
from Dr. Dumur).  A gene ontology analysis using the database for annotation, 
visualization and integrated discovery (DAVID) (Huang, et al., 2009) showed that the 
highest enrichment terms are associated with immune response in both cell lines 67NR 
(Table2) 66cl4 (Table 3).  Genes from 67NR tumors include genes involved in antigen 
presentation on MHC-I molecules (TAP2 and Tapbp), MHC-I genes (H2-D1and H2-L) 
and MHC-II gene (H2-DMa) (Table 4).  As the tumor tissues that were used for the 
microarray experiments might be infiltrated with immune cells, identifying Bptf 
dependent genes will need to be confirmed in cells grown in vitro.  In the preliminary 
results of gene expression in vitro, we didn’t observe overexpression of these genes in 
the two KD cell lines, which suggests that the observed overexpression of these genes 
in the array is due to active immune cells infiltrated into the tumor site (Figure 11 a).  
Indeed, enrichment of lymphocyte-associated genes among the overexpressed probes 
was observed (Table2).   We detected down regulation of cyclin D1 isoform Ccnd1b 
gene which is also down regulated in Bptf KO ESCs and MEFs (Dr. Landry unpublished 
data). 
Genes from 66cl4 tumors include genes involved in antigens presentation on 
MHC-I (Psmb8, Psmb9 and Tapbpl), MHC-I gene (H2-K1), MHC-II gene (H2-DMb2) 
and chemokine genes (Cxcl16, Cxcl9 and Xcl1) (Table 5).  We anticipated that the 
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enrichments of these genes is more likely due to active immune cells infiltrated into the 
tumor site, as the preliminary results of gene expression in vitro did not show 
overexpression of these genes except Cxcl16 (Figure 11 b).  This suggestion is 
supported by the enrichment of T-lymphocyte genes in the overexpressed genes from 
66cl4 tumors (Table 3).   Cxcl16, which is also overexpressed in the cell culture, is a 
chemokine that recognized by chemokine receptor Cxcr6, which is expressed on the 
surface of immune cells e.g. CD8+, CD4+ and NK lymphocytes (Deng, et al., 2010).  
One of the Cxcl16 roles is inducing chemotactic migration for cells that express Cxcr6.   
 Although more tumors are going to be subjected to the microarray and qRT-
PCR, the current data suggested that the immune system is involved in the phenotype 
observed in BALB/c mice.  Complete microarray and in vitro gene expression data will 
be required to identify the potential Bptf-dependent candidate genes. 
 
 
 
 
 
 
Figure 10)   
a) 
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b) 
 
c) 
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d) 
 
 
Figure 10: Microarray Analysis for 67NR and 66cl4 Tumors: 
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a) Unsupervised cluster analysis based on 22,960 probe sets for 67NR tumors using euclidean 
distance and average linkage. Three control tumors and two KD-2 (short hairpin #5) tumors 
were used.   
b) Supervised cluster analysis for 67NR tumors based on 88 significant (p-value < 0.01, False 
discovery date FDR < 12%) probe sets that showed > 2 fold change between the control and 
KD. Three control tumors and two KD-2 (short hairpin#5) tumors were used C) Unsupervised 
cluster analyses based on 22,960 probe sets using centered correlation and average linkage for 
66cl4 tumors. Two tumors for the control, KD-1 (short hairpin #3) and KD-2 (short hairpin #5) 
were used.  
 d) Supervised cluster analysis for 66cl4 tumors based on 105 significant (p-value < 0.01, False 
discovery date FDR < 12%) probe sets that showed > 2 fold change between the control and 
KD. probe sets using centered correlation and average linkage for 66CL4 tumors. Two tumors 
for the control, KD-1 (short hairpin #3) and KD-2 (short hairpin #5) were used. 
 
Table 2) 
 
 
 
Table 2: Enrichments of Terms with Immune Response Function in 67NR Tumors: 
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Gene ontology analysis using DAVID functional annotation chart tools that identify enriched 
annotation terms in a gene list.  Genes list from 67NR tumors for genes that were 
overexpressed with 2 or more fold changes show the highest significant enrichments terms are 
associated with immune response.  
 
 
Table 3) 
 
Table 3:  Enrichments of Terms with Immune Response Function in 66cl4 Tumors: 
Gene ontology analysis using DAVID functional annotation chart tools that identify enriched 
annotation terms in a gene list.  Genes list from 66cl4 tumors for genes that were 
overexpressed with 2 or more fold changes show the highest significant enrichments terms are 
associated with immune response. 
 
 
 
 
 
Table 4) 
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Table 4: Genes from 67NR tumors: 
Candidate genes from 67NR tumors that show significant change compared to control tumors 
(p-value α-level0.001 FDR < 12%).  
 
Table 5) 
 
Table 5: Genes from 66cl4 tumors: 
Candidate genes from 66cl4 tumors that show significant change comparing to control tumors 
(p-value α-level0.001 FDR < 15%) 
 
 
 
Figure 11) 
Gene Title
Gene 
Symbol
Fold 
Change 
(Geometr
ic)
p-value            
(a-level: 
0.01)
q-value 
(FDR≤12
%)
1 transporter 2, ATP-binding cassette Tap2 4.89 2.73E-03 1.18E-01
2 histocompatibility 2, class II, locus DMa H2-DMa 4.12 1.60E-03 1.12E-01
3 TAP binding protein Tapbp 3.27 3.07E-04 1.12E-01
4 histocompatibility 2, D region locus 1 H2-D1 2.09 1.79E-03 1.12E-01
5 histocompatibility 2, D region H2-L 2.07 6.79E-04 1.12E-01
Gene Title
Gene 
Symbol
Fold 
Change 
(Geometr
ic)
p-value          
(a-level: 
0.01)
q-value 
(FDR≤15
%)
1 proteasome (prosome, macropain) subunit, beta type 9 Psmb9 2.4 1.21E-04 1.21E-01
2 TAP binding protein-like Tapbpl 1.8 7.32E-03 1.47E-01
3 histocompatibility 2, class II, locus Mb2 H2-DMb2 1.6 4.74E-03 1.47E-01
4 chemokine (C-X-C motif) ligand 16 Cxcl16 2.4 3.38E-03 1.47E-01
5 chemokine (C-X-C motif) ligand 9 Cxcl9 5.1 6.75E-03 1.47E-01
7 proteasome (prosome, macropain) subunit, beta type 8 Psmb8 2.4 2.38E-03 1.47E-01
8 histocompatibility 2, K1, K region H2-K1 1.7 6.84E-03 1.47E-01
9 chemokine (C motif) ligand 1 Xcl1 2.4 1.95E-03 1.47E-01
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a) 
 
b) 
 
Figure 11: Q RT-PCR for 67NR and 66cl4 Breast Cancer Cell Lines: 
a) Differential gene expression of Tapbp, H2-Mb2, Tap1, Tap2, H2-D1, H2-Dma, Ccnd1a, 
Ccnd1b and Bptf were analyzed in the 67NR breast cancer cell lines using qRT-PCR.  β-
actin was used as a housekeeping gene for normalization. Error bars represent standard 
deviation of two biological replicates. 
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b) Differential gene expression of Cxcl16, H2-Mb2, Psmb8, Psmb9, H2-D1, H2-K1, Cxcl9, 
Ccnd1a, Ccnd1b and Bptf were analyzed in the 666cl4 breast cancer cell lines using 
qRT-PCR.  β-actin was used as a housekeeping gene for normalization. Error bars 
represent two biological replicates for Cxcl16, Psmb8, Psmb9, H2-D1, H2-K1, Ccnd1a 
and Bptf. 
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4- Discussion and Future Directions 
 
 
4.1- Discussion. 
Epigenetic alterations are important factors in tumorigenesis (Jones & Baylin, 
2002).  The reversible nature of epigenetic changes makes these types of aberrant 
alterations potential targets for cancer therapy.  Extensive research in understanding 
DNA methylation and histone modifications provide broad understanding of these 
mechanisms, which led develop drug therapies targeting these mechanisms (Sharma, 
et al., 2010).  Chromatin remodeling complexes are epigenetic regulators that affect 
gene expression by changing the chromatin structure (Clapier & Cairns, 2009).  NURF 
is an ATP-chromatin remodeling complex that is essential for normal embryonic 
development through regulating important developmental pathways (Landry, et al., 
2008).  ESCs lacking NURF through KO of its unique subunit Bptf were unable to form 
teratomas in NOD/SCID mice (Landry, et al., 2008).  Moreover, Bptf KO in ESCs, MEFs 
and DP thymocytes showed deregulation of genes involved in tumor progression e.g. 
MHC-I molecules and E- and N- cadherin genes (Landry, et al., 2008) (Landry, et al., 
2011).   These findings suggested that NURF might have an impact on tumor growth.  
Prior to this work, the role of mammalian NURF in tumorigenesis was unknown.   
The subject of the current work is to study the role of NURF in tumorigenesis in 
vivo.  We hypothesized that eliminating NURF function might reduce tumor growth in 
vivo.  Our findings suggest that abolishing NURF function in tumor cells reduces the 
tumor growth in the presence of intact immune system. 
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We used a syngeneic breast cancer mouse model to study the impact of eliminating 
NURF on tumor growth.  Using shRNA technology we generated two stable KD breast 
cancer cell lines with two different shRNA targeting NURF essential subunit Bptf.  In 
order to investigate the impact of eliminating NURF in the tumor growth in vivo, we 
injected the Bptf KD breast cancer cell lines into the mammary fat pad of BALB/c mice.  
After three weeks of injection of the 67NR cells, we found significant reduction in tumor 
growth in mice injected with KD cell lines comparing to mice injected with control cells.  
While 12 out of 13 mice injected with the control cells formed tumors, only 3 out of 13 
and 6 out 16 mice injected with KD-1 and KD-2 cells, respectively, developed tumors.  A 
similar reduction in tumor size but not frequency was observed with the 66cl4 breast 
cancer cells (work done by S. Alkhatib data not shown).    Reduction in primary tumor 
growth in BALB/c derived 4T1 breast cancer mouse model have been observed in 
number of study that target genes involved in tumor survival (Nasrazadani & Lynn Van 
Den Berg, 2011) (Hong, et al., 2009) .  One study showed significant reduction in 
mammary tumor growth in mice injected with 4T1breast cancer cells stably express 
shRNA targeting IL-17 receptor (Nam, et al., 2008).  These tumor cells were less 
response to IL-17 that is secreted by immune cells such as CD8+ T-cells which acts as 
survival signal for tumor cells.   
 
Next, it was important to determine if the observed reduction in tumor growth is 
due to a change in growth capacity in vitro following Bptf KD.  By measuring the 
population doubling time for the breast cancer cell lines in vitro, we found that KD of 
Bptf does not affect the growth capacity of the tumor cells.  The obtained population 
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doubling time in our experiment is similar to previously published results (Eckhardt, et 
al., 2005).  This suggests that the observed reduction in tumor growth is due to an effect 
that the tumor cells encounter in vivo.   
One important step during tumor growth is the ability of the transformed cells to 
avoid the antitumor response mediated by the host immune system (Dunn, et al., 2004) 
(Hanahan & Weinnerg, 2011).   As previously observed in vitro that Bptf deregulates 
MHC-I and MHC-II genes (Landry, et al., 2008), which are important for proper immune 
response.  Deregulation of MHC-I and MHC-II genes are observed in number of tumors 
such as breast cancer, prostate cancer and melanoma (Campoli & Ferrone, 2008).  We 
hypothesized that the immune system might preferentially target the Bptf KD tumors 
cells.  To test this, we used NSG mouse model which has loss of functional innate and 
adaptive immune system.  Bptf KD-1, KD-2 and control 67NR breast cancer cell lines 
were injected into the mammary fat pad of these mice with the same number of cells 
that were injected in the BALB/c mice.  After three weeks of injection, all the mice 
injected with the KD-1, KD-2 and control cells developed tumors.  The obtained tumor 
weights showed no significance difference between the KDs and control tumors.  
Similar finding was obtained using the 66cl4 cells (work done by S. Alkhatib data not 
shown).   
Our finding that showed reduction in tumor growth in BALB/c mice but not in 
immunodeficient mice in agreement with previously published results that showed a 
significant reduction in primary tumor growth in BALB/c mice but not in immunodeficient 
mice after injection with 4T1 breast cancer cells lacking indolamine 2,3-dioxgenase that 
promote immune escape capability of the transformed cells.   In this study, KD of 
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indolamine 2,3-dioxgenase (IDO1) which is an enzyme responsible for tryptophan 
catabolism in 4T1 cells showed reduction in tumor growth after injection of these cells 
into the syngeneic BALB/c mice but not in mice lacking functional immune system 
(Levina, et al., 2012).   Over expression of IDO1 in tumor microenvironment is known to 
promote tumor cells to escape the antitumor immune response likely by inhibiting T-
cells activity (Prendergast, 2008).  This suggests a similar role of NURF in transformed 
cells, in which Bptf KD in tumor cells; promote active antitumor immune response 
against these cells.   
The antitumor response of the immune system is mediated mainly through the 
cellular components of the innate and the adaptive immune system like NK, CTLs and 
T-helper cells.  While the antitumor role and the favorable outcome are associated with 
lymphocytes infiltration into the tumor microenvironment (Naito, et al., 1998), MDSCs 
are known to oppose the immune response and act as immunosuppressive cells 
(Gabrilovich & Nagaraj, 2009).  We screened for CTLs, T-helper, NK and MDSCs cells 
infiltration into the tumor tissues isolated form the BALB/c mice injected with 67NR and 
66cl4 breast cancer cell lines using immunofluorescence staining with antibodies for 
CD8a (CTLs), CD4 (T-helper cells), NKp46 (NK cells) and CD11b (MDSCs).  As not all 
the mice injected with the 67NR KD cells form tumors, we only subjected one tumor for 
KD-1 and two tumors for KD-2 for the staining.  We observed a relative increase in 
CD8a and CD4 and decrease in CD11b from KD-2 tumors.  However, more tumors 
need to be used in order to confirm the significance of any observed findings.  From 
mice injected with the 66cl4 cells, we did not observe a significant difference between 
the control and KD tumors in the CD8a, CD4, NKp46 and CD11b cells.  Although no 
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significant increase in the immune cells infiltration into KD tumor microenvironments, 
there might be an increase in the cells efficiency or activity in or decrease in regulatory 
cells that have immunosuppressive role, which can’t be distinguish by using single 
antibody for each cell type (Rosenberg, 2001) (Zitvogel, et al., 2006).  In order to 
differentiate between the effector T-cells and regulatory T-cell populations infiltrated into 
the tumor sites, fluorescence activated cell sorting (FACS) analysis needs to be 
performed using specific markers for each cell type such as Fox3+ that distinguish 
regulatory T-cells from effector T-cells (Bui, et al., 2006). 
To identify NURF dependent genes in tumor cells, we subjected the tumor 
tissues isolated from BALB/c mice to microarray analysis.  From our preliminary 
microarray data we observed enrichment of genes involved in immune response 
pathways.  Among the overexpressed genes from the 66cl4 KD tumors, there is 
enrichment of lymphocyte-associated genes, which indicates infiltration of active 
immune cells into the KD tumors.  The observed overexpression of MHC-I, MHC-II and 
APM (Psmb7and Psmb8) genes in the array is more likely due to immune cells 
infiltration since the qRT-PCR experiment showed down regulation of these genes in 
the tumor cells in vitro.   Another group of genes that is overexpressed in 66cl4 tumors 
is a set of chemokines (Cxcl16, Xcl1 and Cxcl9) which induce the migration of the 
immune cells.  Cxcl16 is of particular interest since it is also overexpressed in 66cl4 cell 
lines in vitro, and it has a role in immune cells infiltration (Hojo, et al., 2007).  A 
colorectal cancer study showed an association between Cxcl16 expression in tumor 
cells and CD4+ and CD8+ T-lymphocyte infiltration (Hojo, et al., 2007). In this study it 
has been shown that overexpression of Cxcl16 also associated with favorable 
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prognosis.  Xcl1 is another chemokine that induce infiltration of CD8+ dendritic cells in 
mouse and CD141+dendritic cells in human which are specialized in antigen 
presentation to CTLs and augment CTL cytotoxic activity (Lei & Takahama, 2012).  A 
study in human breast cancer cell lines showed overexpression of XCL1 following 
treatment with DNA methylation and histone acetylation inhibitors (Keen, et al., 2004). 
In order to confirm whether Xcl1 expression is Bptf dependent, the expression will be 
tested using 66cl4 cell lines grown in vitro.  Cxcl9 is a chemokine that induce attraction 
for immune cells, and it has antitumor immune response (Walser, et al., 2007).  The 
preliminary result from in vitro gene expression for one replicate showed down 
regulation of Cxcl9.  More samples need to be tested to confirm whether Cxcl9 is Bptf-
dependent or not.   
Data from the 67NR only represent 2 tumors for the KD-2 and 3 tumors for the 
control. We also, observed enrichment of genes involved in the immune response in the 
KD tumors.  The observed overexpression of MHC-I (H2-D1), MHC-II (H2-Dma) and 
APM (Tapbp and TAP2) in the microarray but not in cells growing in vitro more likely 
was due to immune cells infiltration.  We detected down regulation of cyclin D1 b 
isoform in vitro.   This in agreement with a previous finding that showed cyclin D1 down 
regulation in Bptf KO ESCs, MEFs (Dr. Landry unpublished data).   Along with its 
classical role as a cell cycle regulator, cyclin D1 plays a role as a regulator of gene 
transcription through its interaction with transcription factors as well as HATs and 
HDACs coactivators (Velasco-Velazquez, et al., 2011).   We did not observe a reduction 
in cell growth in vitro and tumor growth in NSG mice, which indicates that reduction of 
cyclin D1 does not affect the cellular proliferation in Bptf KD cells.  Knockout of cyclinD1 
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promote MEF differentiation to adipocyte, which indicates that cyclinD1 involved 
regulation of genes control this differentiation  (Fu, et al., 2005).  Down regulation of 
cyclin D1 in the 67NR might altered expression of genes that enhance the tumor cell 
immunogenicity e.g. overexpression of genes that might serve as tumor associated 
antigens and enhance the tumor cell recognition by the immune cells. Currently we 
don’t have complete data from KD-1 and KD-2 67NR tumors.  We expect that more 
tumors will help in identifying set of genes, such as chemokines, that might account for 
the observed phenotype. 
The microarray experiment is currently ongoing and we anticipate that complete 
microarray and qRT-PCR data will provide us with a better set of potential NURF-
dependent candidate genes that account for the observed phenotype in tumor growth.   
In conclusion, our findings that KD Bptf reduces tumor growth in vivo with an 
intact immune system, but not in vitro, and that reduction is retained in immunedepleted 
mice support our hypothesis that eliminating NURF function in tumor cells reduces the 
tumor growth in vivo likely through an increased active antitumor immune response.  At 
present time we don’t have complete data from the microarray and qRTpPCR to identify 
the Bptf dependent genes that account for the observed phenotype. However, 
enrichment of genes associated with immune response supports the role of the immune 
system in the observed phenotype.  
 
4.2- Future Directions. 
The ultimate goal for studying roles of NURF in tumorigenesis is to provide 
complete understanding of how NURF might be involved in tumor growth.  Four 
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questions need to be addressed in order to achieve this goal. First, what component of 
the immune system is active against tumor cells lacking Bptf?  Second, what are the 
NURF dependent genes that underlie the observed phenotype?  Third, is the observed 
phenotype specific for the breast cancer models or similar finding can be obtained in 
other solid tumor models?  Fourth, does the observed phenotype also occur in 
humans?. 
As the data suggests that eliminating NURF in tumor cells promotes the 
antitumor immune response, it is important to determine what component of the immune 
system is involved.  The two important main cells that mediate the tumor cytotoxicity are 
NK and CTL cells (Russell & Ley, 2002).  To answer this question investigation of the 
NK and CTL activity against Bptf KD tumor cells in vitro will be performed.   Next, the in 
vitro study will be followed by in vivo study using animal model lacking the immune 
effector cell population either by genetic modification or antibody treatment.  
Complete data from the microarray will provide a set of candidate genes that are 
NURF dependent. Molecular analysis will be performed to identify the role of NURF in 
regulating these genes. DNase I-hypersensitivity analysis and chromatin 
immuneprecipitation (ChIP) assay will help to determine whether NURF directly 
regulates these genes.   
It is important to determine whether the role of NURF in tumor growth is not 
limited to the breast cancer model that is used in this work. Towered this end, studying 
the effect of NURF in other solid tumor models e.g. melanoma, will be essential.   
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Finally, many promising gene targets using mouse models don’t translate to 
human therapies.  It is important to know if NURF dependent pathways and genes 
identify in the mouse model also apply to human. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
59 
 
References 
 
Moazed, D., 2011. Mechanisms For the Inheritance of Chromatin States. Cell , Aug.pp. 510-518. 
Shinkai, Y. et al., 1992. RAG-2-deficient mice lack mature lymphocytes owing to inability to 
initiate V(D)J rearrangement. Cell, 68(5), pp. 855-867. 
Vermeulen, K., Van Bockstaele, D. R. & Berneman, Z. N., 2003. The cell cycle: a review of 
regulation, deregulation and therapeutic targets in cancer. Cell Proliferation , 36(3), pp. 131-
149. 
Algarra, I., Collado , A. & Garrido, F., 1997. Altered MHC class I antigens in tumors. Int. J. Clin. 
Lab. Res., Volume 27, pp. 95-102. 
Alkhatib, s. & Landry, J., 2011. The Nucleosome Remodeling Factor. FEBS Letters, 585(20), pp. 
3197-3207. 
American Cancer Society. , 2012. Cancer Facts & Figures 2012.. Atlanta: American Cancer 
Society; 2012. 
Angeles, A., Fung, G. & Luo, H., 2012. Immune and non-immune functions of the 
immunoproteasome. Front. Biosci, Volume 17, pp. 1904-16. 
Aslakson, C. & Miller, F., 1992. Selective Events in the Metastatic Process Defined by Analysis of 
the Sequential Dissemination of Subpopulations of a Mouse Mammary Tumor. Cancer research 
, Volume 52, pp. 1399-1405. 
Badenhorst, P., Voas, M. V., Rebay, I. & Wu, C., 2002. Biological functions of the ISWI chromatin 
remodeling complex NURF. Genes Dev., 16(24), p. 3186–3198.. 
Barak, O. et al., 2003. Isolation of human NURF: a regulator of Engrailed gene expression. EMBO 
J., 22(22), pp. 6089-6100. 
Berdasco, M. & Esteller, M., 2010. Aberrant Epigenetic Landsape in Cancer: How Cellular 
Identity Goes Awry. Cell press, Nov.pp. 698-711. 
Bertram, J., 2000. The molecular biology of cancer. Molecular Aspects of Medicine, 21(6), p. 
167–223. 
Birkeland, S. et al., 1995. Cancer risk after renal transplantation in the nordic countries, 1964-
1986. Int J Cancer, 60(2), pp. 183-189. 
Biron , C. et al., 1987. Murine natural killer cells stimulated in vivo do not express the T cell 
receptors alpha, beta, gamma, T3 delta or T3 epsilon genes. The journal of immunology, 
Volume 139, pp. 1704-100. 
Buganim, Y. et al., 2010. A novel translocation breackpoint within the BPTF gene is associated 
with a pre-malignant phenotype.. PLoS one, 5(3), p. e9657. 
Bui, J., Uppaluri, R., Hesieh, C.-S. & Schreiber, R., 2006. Comparative analysis of regulatory and 
effectore T cells in progressively growing versus rejecting tumors of similar origins. Cancer 
reserch, 66(14), pp. 7301-09. 
Burnet, F., 1970. The concept of immunological survillance. Prog. Exp. Tumor Res., Volume 13, 
pp. 1-27. 
Campoli, M. & Ferrone, S., 2008. HLA antigen changes in malignant cells: epigenetic mechanism 
and biological significance. Oncogene, 27(45), pp. 5869-85. 
Clapier, C. R. & Cairns, B. R., 2009. The Biology of Chromatin Remodeling Complexes. Annu. Rev. 
Biochem., Volume 78, pp. 273-304. 
60 
 
Coca, S. et al., 1997. The prognostic significance of intratumoral natural killer cells in patients 
with colorectal carcinoma.. Cancer. 1997 Jun 15;79(12):2320-8., 79(12), pp. 2320-2328. 
Deng, L. et al., 2010. CXCR6/CXCL16 functions as a regulator in metastasis ans progression of 
cancer. Biochimica et Biophysica Acta (BBA), 1806(1), pp. 42-49. 
Di Croce, L. et al., 1999. Two-Step Synergism between the Progesterone Receptor and the DNA-
Binding Domain of Nuclear Factor 1 on MMTV Minichromosomes. Mol. Cell, 4(1), pp. 45-54. 
Diefenbach, A., Jensen, E., Jamieson, A. & Raulet, D., 2001. Rea1 and H60 ligands of the NKG2D 
receptor stimulate tumor immunity. Nature, Volume 413, pp. 165-171. 
DiSanto, J. et al., 1995. Lymphoid development in mice with a targetd deletion of the 
interleukin 2 receptor gamma chain. Proc Natl Acad Sci PNAS, 92(2), pp. 377-381. 
Dumur, C. et al., 2008. Assessing the Impact of Tissue Devitalization Time on Genome-wide 
Gene Expression Analysis in Ovarian Tumur Samples. Diagn Mol Pathol, 17(4), pp. 200-206. 
Dunn, G., Old, L. & Schreiber, R., 2004. The Three Es of Cancer Immunoediting. Annu. Rev. 
Immunol., Volume 22, pp. 329-360. 
Eckhardt, B. et al., 2005. Genomic analysis of a spontaneous model of breast cancer metastasis 
to bone reveals a role for the extracellular matrix. Mol. Cacer Res., Volume 3, pp. 1-13. 
Egger, G., Liang, G., Aparicio, A. & Jones, P., 2004. Epigenetics in Human Disease and Prospects 
for Epigenetics therapy. Nature, May.pp. 457-463. 
Ferlay , J. et al., 2010. GLOBOCAN 2008 v1.2, Cancer Incidence and Mortality Worldwide: IARC 
CancerBase No. 10 [Internet].. International Agency for Research on Cancer: Lyon, France.. 
Gabrilovich, D. & Nagaraj, S., 2009. Myeloid-derived-suppressor cells as regulators of the 
immune system. Nat. Rev. Immunol., 9(3), pp. 162-174. 
Garrido, F. et al., 1997. Implications for immunosurveillance of altered HLA class I phenotypes in 
human tumours. Immunology Today, 18(2), pp. 89-95. 
Goldman, J., Garlick, J. & Kingston, R., 2010. Chromatin Remodeling by Imitation Switch (ISWI) 
Class ATP-dependent Remodelers Is Stimulated by Histone Variant H2A.. J. Biol. Chem., Volume 
285, pp. 4645-4651. 
Groh, V. et al., 1999. Broad tumor-associated expression and recognition by tumor derived 
gamma delta T cells of MICA and MICB. Proc. Natl. Acad. Sci. USA , 96(12), pp. 6879-84. 
Hahn, W. & Weinberg, R., 2002. Modelling the molecuar circulatory of cancer. Nature, Volume 
2, pp. 331-341. 
Hamiche, A., Sandaltzopoulos, R., Gdula, D. & Wu, C., 1999. ATP-Dependent Histone Octamer 
Sliding Mediated by the Chromatin Remodeling Complex NURF. Cell, 97(7), pp. 833-842. 
Hanahan , D. & Weinberg, R., 2000. The Hallmarks of Cancer. Cell, Volume 100, pp. 57-70. 
Hanahan, D. & Weinberg, R., 2000. The Hallmarks of Cancer. Cell, Volume 100, pp. 57-70. 
Hanahan, D. & Weinnerg, R., 2011. Cell, 144(5), pp. 646-674. 
Hanahan, D. & Weinnerg, R., 2011. Hallmarks of Cancer: The Next Generation. Cell, 144(5), pp. 
646-74.. 
Hojo, S. et al., 2007. High-level expression of chemokine CXCL16 by tumor cells correlates with a 
good prognosis and increased tumor infiltrating lymphocytes in colorectal cancer. Cancer 
research , Volume 67, pp. 4725-31. 
Huang, D., Sherman, B. & Lempicki, R., 2009. Bioinformatics enrichment tools: paths toward the 
comprehensive functional analysis of large gene lists. Nuclic Acids Res., 37(1), pp. 1-13. 
61 
 
Huang, D., Sherman, B. & Lempicki, R., 2009. Systematic and integrative analysis of large gene 
lists using DAVID bioinformatics resource. Nature Protocols, Volume 4, pp. 44-57. 
Ikeda, H., Old, L. & Schreiber, R., 2002. The roles of INF-gamma in protaction against tumor 
development and cancer immunoediting. Cytokine & Growth Factor Reviews, Volume 13, pp. 
95-109. 
Ishigami, S. et al., 2000. Prognostic value of intratumoral natural killer cells in gastric 
carcinoma.. Cancer, 88(3), pp. 577-83. 
Jones, P. & Baylin, S., 2002. The Fundamental Role of Epigenetic Event in Cancer. Nature 
Reviews, Volume 3, pp. 415-428. 
Jordan Sciutto, . K. et al., 1999. Fetal Alz-50 Clone 1, a Novel Zinc Finger Protein, Binds a Specific 
DNA Sequence and Acts as a Transcriptional Regulator. Journal of Biological Chemistry, 274, pp. 
35262-68. 
Karlhofer, F., Ribaudo, R. & Yokoyama, W., 1992. MHC class-I alloantigen specificity of Ly-49+ IL-
2-activated natural killer cells. Nature, Volume 358, pp. 66-70. 
Keen, J. et al., 2004. Epigenetic regulation of protein phosphatas 2a (PP2A), lymphotactin (XCL1) 
and estrogen receptor alpha (ER) expression in human breast cancer cells. Cancer biology and 
therapy, 3(12), pp. 1304-12. 
Khong, H. & Restifo, N., 2002. Natural selection of tumor variants in the generation of "tumor 
escape" phenotypes. Nat Immunol. , 3(11), pp. 999-105. 
Kidd, P., 2003. Th1/Th2 Balance: The hypothesis, its limitations, and implication for health and 
disease. Alternative Medicine Review, Volume 8, pp. 223-246. 
Kiessling, R., Klein, E. & Wigzell, H., 1975. Natural” killer cells in the mouse. I. Cytotoxic cells 
with specificity for mouse Moloney leukemia cells. Specificity and distribution according to 
genotype. European Journal of Immunology , 5(2), pp. 112-117. 
Kim, J., Samaranayake, M. & Pradhan, S., 2009. Epigeneic Mecahnisms in mammals. Cell. Mol. 
Life. Sci, Volume 66, pp. 596-612. 
Koh, C. et al., 2001. Augmentation of antitumor effects by NK cell inhibitory receptor blocked in 
vitro an in vivo. Blood, 97(10), pp. 3132-37. 
Kwon, S. Y. et al., 2008. The nucleosome remodeling factor (NURF) regulates genes involved in 
Drosophila innate immunity. 316(2), pp. 538-547. 
Landry, J. et al., 2011. Chromatin remodeling Complex NURF regulated thymocyte maturation. 
Genes and development, Volume 25, pp. 275-286. 
Landry, J. et al., 2008. Essential Role of Chromatin Remodeling Protein Bptf in Early Mouse 
Embryos and Embryonic Stem Cells. PLOS Genetics, 4(10), p. e1000241. 
Langers, I. et al., 2012. Natural killer cells: role in local tumor growth and metastasis. Biologics: 
targets and therapy, Volume 6, pp. 73-82. 
Lei, Y. & Takahama, Y., 2012. XCL1 and XCR1 in the immune system. Microbes and Infection, 
Volume 14, pp. 262-267. 
Lelekakis,, M. et al., 1999. A novel orthotopic model of breast cancer metastasis to bone. 
CLINICAL AND EXPERIMENTAL METASTASIS, Volume 17, pp. 163-170. 
Luger, K. et al., 1997. Crystal structure of the nucleosome core particle at 2.8 Å resolution. 
Nature , Volume 389, pp. 251-260. 
Makrilia, N., Kollias, A., Manolopoulos, L. & Syrigos, K., 2009. Cell adhesion molecules: role and 
clinical significance in cancer.. Cancer Invest. 2009 Dec;27(10):1023-37., 27(10), pp. 1023 -37. 
62 
 
Manning, J. et al., 2007. Induction of MHC-I molecule cell surface expression and epigenetic 
activation of antigene machinery components in a murine model for human papilloma virus 16-
associated tumors. Immunology , Volume 123, pp. 218-227. 
Medzhitov, R., 2007. Review Article Recognition of microorganisms and activation of the 
immune response. Nature, Volume 449, pp. 819-826. 
Millau, J.-F. & Gaudreau, L., 2011. CTCF, cohesin, and histone variants: connecting the genome. 
Biochem. Cell. Biol., Volume 89, pp. 505-513. 
Naiditch, H., Shurin, M. & Shurin, G., 2011. Targeting myloid regulatory cells in cancer by 
chemotheraputic agents. Immunol Res, Volume 50, pp. 276-285. 
Naito, Y. et al., 1998. CD8+ T cells infiltrated within cancer cell nests as a prognostic factor in 
human colorectal cancer. Cancer research , Volume 58, pp. 3491-94. 
Ottewell, P., Coleman, R. & Holen, I., 2006. From genetic abnormality to metastasis: murine 
models of breast cancer and their use in the development of anticancer therapies. Breasr 
Cancer Research and Treatment, Volume 96, pp. 101-113. 
Piersma, S., Welters, M. & van der Burg, S., 2008. Tumor-specific regulatory T cells in cancer 
patients. Human Immunology , 69(4-5), p. 241–249. 
Pieters, J., 1997. MHC class II restricted antigen presentation. Current Opinion in Immunology, 
9(1). 
Restifo, N., Dudley, M. & Resenberg, S., 2012. Adoptive immunotherapy for cancer: harnessing 
the T cells response. Nature reviews, Volume 12, pp. 269-281. 
Rosenberg, S., 2001. Progress in huma tumor immunology abd immunotherapy. Nature, 
Volume 411, pp. 380-384. 
Russell, J. & Ley, T., 2002. LYMPHOCYTE-MEDIATED CYTOTOXICITY. Annu. Rev. Immunol. , 
Volume 20, pp. 323-70. 
Schametterer, K., Neunkirchner, A. & Pickl, W., 2012. Naturally occuring regulatory T cells: 
markers, mechanisms, and manipulation. FASEB J., 26(6), pp. 2253-76. 
Seliger, B., 2008. Volume 57, pp. 1719-26. 
Seliger, B., 2008. Molecular mechanisms of MHC class I abnormalities and APM components in 
human tumors. CANCER IMMUNOLOGY, IMMUNOTHERAPY, Volume 57, pp. 1719-26. 
Seliger, B., Maeurer, M. & Ferrone, S., 2000. Immunology today, 21(9), pp. 455-464. 
Seliger, B., Maeurer, M. & Ferrone, S., 2000. Antigene processing machinary breakdown and 
tumor growth. Immunology today, 21(9), pp. 455-464. 
Shankaran, V. et al., 2001. INF-gamma and luymphocytes prevent primary tumor development 
and shape tumor immunogenicity. Nature, Volume 410, pp. 1107-11. 
Sharma, S., Kelly, T. & Jones, P., 2010. Epigenetics in Cancer. Carcinogenesis, pp. 27-33. 
Sharma, S., Kelly, T. & Jones, P., 2010. Epigenetics in Cancer. Carcinogenesis, 31(1), pp. 27-33. 
Singh, S. et al., 2011. A complex of Nuclear Factor I-X3 and STAT3 Regulates Astrocyte and 
Glioma Migration through the Secretd Glycoportein YKL-40. The Journal of Biological Chemistry 
, 286(46), pp. 39893-39903. 
Smyth, M., Crowe, N. & Godfrey, D., 2001. International immunology, 13(4), pp. 459-463. 
Smyth, M., Crowe, N. & Godfrey, D., 2001. NK cells and NKT cells collarborate in host protection 
from methylcholanthrene-induced fibrosarcoma. International immunology, 13(4), pp. 459-463. 
Smyth, M., Godfrey, D. & Trabani, J., 2001. A fresh look at tumor immunosurvillance and 
immunotherapy. Nature Immunology, 2(4), pp. 293-299. 
63 
 
Tomasi, T., Manger, W. & Khan, N., 2006. Epigenetic regulation of immune escape genes in 
cancer. Cancer immunol immunother, Volume 55, pp. 1159-84. 
Tsukiyama, T. & Wu, C., 1995. Purification and properties of an ATP-dependent nucleosome 
remodeling factor. Cell , 83(6), pp. 1011-1020. 
Valastyan , S. & Weinberg, R., 2011. . Cell, 147(2), pp. 275-292. 
Valastyan, S. & Weinberg, R., 2011. Tumor Metastasis: Molecular Insights and Evolving 
Paradigms. Cell, Volume 147, pp. 275-291. 
Velasco-Velazquez, M. et al., 2011. Examining the role of cyclin D1 in breast cancer. Future 
oncology, 7(6), pp. 753-765. 
Vesely, M., Kershaw, M., Schreiber, R. & Smyth, M., 2011. Natural Innate and Adaptive 
Immunity to cancer. Annu. Rev. Immunol, Volume 29, pp. 235-271. 
Walser, T. et al., 2007. Immune-mediated Modulation of breast cancer growth and metastasis 
by the chemokine Mig (CXCL) in a murine model. J . immunother, 30(5), pp. 490-498. 
Wang, G., Allis, C. & Chi, P., 2007. Chromatin Remodeling and Cancer, Part II: ATP-dependent 
chromatin remodelin. TRENDS in Molecular Medicine, 13(9), pp. 373-380. 
Wang, R. F., 2008. CD8+ regulatory T cells, their suppressive mechanisms, and regulation in 
cancer. Human Immunology, Volume 69, pp. 811-814. 
Wysocka, J. et al., 2006. A PHD finger of NURF couples histone H3 lysine 4 trimethylation with 
chromatin remodelling. Nature, Volume 442, pp. 86-90. 
Xiao, H. et al., 2001. Dual functions of largest NURF subunit NURF301 in nucleosome sliding and 
transcription factor interactions. Molecular Cell, 8(3), pp. 531-543. 
Yu, P. & Fu, Y.-X., 2006. Tumor-infiltrating T lymphocytes: freinds or foes?. Laboratory 
investigation, Volume 86, pp. 231-245. 
Zamai, L. et al., 1998. Natural Killer (NK) Cell–mediated Cytotoxicity: Differential Use of ￼TRAIL 
and Fas Ligand by Immature and Mature Primary Human NK Cells. J Exp Med. , 188(12), p. 
2375–2380. 
Zitvogel, L., Tesniere, A. & Kroemer, G., 2006. Cancer despite immunosurvillence: 
immunoselection and immunosubervision. Nature reviews immunology, Volume 6, pp. 715-727. 
 
 
 
 
 
 
 
 
 
64 
 
Vita 
 
Aiman Saud Alhazmi was born in July 21st 1984, in Mecca, Saudi Arabia.  He finished 
his high school in Riyadh, Saudi Arabia in 2002.  He graduated from King Saud 
University, Riyadh, Saudi Arabia in 2007 with B.Sc. in Clinical Laboratory Sciences.  In 
2009, Aiman received a scholarship from King Saud bin Abdul-Aziz University for Health 
Sciences to pursue his graduate study in the field of human and molecular genetics.  He 
joined the department of Human and Molecular Genetics at Virginia Commonwealth 
University in 2010.  While at Virginia Commonwealth University he was awarded the 
C.C. Clayton award for academic excellence in 2011.  Also, he nominated by the 
department for membership into Phi Kappa Phi honor society in 2011. 
 
 
